The present invention relates to synthetic and/or recombinant consensus allergens and to their use as allergy vaccines in particular in the treatment of peach-cypress allergy, in the form of an allergy vaccine comprising a consensus allergen and/or a nucleic acid sequence encoding such, wherein the consensus allergen comprises at least (60) amino acids and is derived from a consensus sequence of the amino acid sequences of at least five (5) protein allergens, and wherein said protein allergens share at least 20% amino acid sequence identity.

Original languageEnglish
IPCC07K 14/ 00 A I
Patent numberWO2023242436
Filing date05/04/2023
Country/TerritoryInternational Bureau of the World Intellectual Property Organization (WIPO)
Priority date05/04/2023
Priority numberEP20230166732
Publication statusPublished - 21 Dec 2023


Dive into the research topics of 'Allergy vaccines based on consensus allergens'. Together they form a unique fingerprint.

Cite this